Chemomab Therapeutics annual depreciation and amortization
2018
2019
2020
2021
2022
2023
2024
2025
Chemomab Therapeutics Depreciation & Amortization Growth & History (CMMB)
Chemomab Therapeutics's depreciation and amortization was $70,000 for fiscal 2025.
View full Chemomab Therapeutics company overviewChemomab Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $70,000 | $17,000 | +32.08% |
| 2024 | 2024-12-31 | $53,000 | −$14,000 | −20.90% |
| 2023 | 2023-12-31 | $67,000 | $9,000 | +15.52% |
| 2022 | 2022-12-31 | $58,000 | $24,000 | +70.59% |
| 2021 | 2021-12-31 | $34,000 | $10,000 | +41.67% |
| 2020 | 2020-12-31 | $24,000 | −$257,000 | −91.46% |
| 2019 | 2019-12-31 | $281,000 | $215,000 | +325.76% |
| 2018 | 2018-12-31 | $66,000 | — | — |
Chemomab Therapeutics quarterly depreciation and amortization
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2023 | 2023-06-30 | $16,000 | $2,000 | +14.29% |
| Q1 2023 | 2023-03-31 | $16,000 | $3,000 | +23.08% |
| Q3 2022 | 2022-09-30 | $17,000 | $8,000 | +88.89% |
| Q2 2022 | 2022-06-30 | $14,000 | $7,000 | +100.00% |
| Q1 2022 | 2022-03-31 | $13,000 | $6,000 | +85.71% |
| Q3 2021 | 2021-09-30 | $9,000 | $1,000 | +12.50% |
| Q2 2021 | 2021-06-30 | $7,000 | $2,000 | +40.00% |
| Q1 2021 | 2021-03-31 | $7,000 | $2,000 | +40.00% |
| Q3 2020 | 2020-09-30 | $8,000 | −$20,000 | −71.43% |
| Q2 2020 | 2020-06-30 | $5,000 | −$16,000 | −76.19% |
| Q1 2020 | 2020-03-31 | $5,000 | −$16,000 | −76.19% |
| Q3 2019 | 2019-09-30 | $28,000 | — | — |
| Q2 2019 | 2019-06-30 | $21,000 | — | — |
| Q1 2019 | 2019-03-31 | $21,000 | — | — |
Chemomab Therapeutics depreciation and amortization trends
Over the last five fiscal years, Chemomab Therapeutics's depreciation and amortization increased from $24,000 to $70,000, a change of $46,000. The latest reported quarter, Q2 2023, shows $16,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Chemomab Therapeutics source filings ↗